Ajuforrestin Aは,STAT3/FAKシグナル伝達経路とVEGFR-2を標的として,腫瘍の増殖と移動を抑制する
Sibei Wang1, Yeling Li1, Mingming Rong1
1State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy, and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Tianjin 300350, China.
Biology
|September 4, 2025
まとめ
Ajuforrestin Aは天然の化合物で,重要なシグナル伝達経路とVEGFR-2を標的として,非小細胞肺がん (NSCLC) の成長,転移,および血管新生を効果的に抑制します. このディターペノイドは 新種の肺がん治療薬として有望です
科学分野:
- 自然製品による薬物発見
- 癌の生物学
- 分子薬理学
背景:
- 抗がん剤の新鮮な可能性が生まれます
- 肺がんは世界的な健康問題です
- 血管新生をターゲットにすることが 癌の治療に不可欠です
研究 の 目的:
- アジュガ・ルプリナのアジュフォレスティンAの抗がん性を調査する.
- 肺がんに対するアジュフォレスティンAの作用の仕組みを明らかにする.
- アジュフォレスティンAの血管新生抑制と転移抑制の性質を評価する.
主な方法:
- A549細胞を用いた細胞増殖,細胞サイクル,アポトーシス試験.
- STAT3とFAK信号を評価するウェスタン・ブロット分析.
- 血管新生と腫瘍の成長を研究するためのゼブラフィッシュモデル (Tg: EGFP) とクセノグラフト.
- VEGFR-2の相互作用研究のための表面プラズモン共鳴 (SPR)
主要な成果:
- アジュフォレスティンAはA549肺がん細胞増殖を抑制し,G0/ G1細胞サイクル停止とアポトーシスを誘発した.
- STAT3とFAKの信号伝達経路を調節し,がん細胞の移動を減少させた.
- アジュフォレスティンAは選択的にVEGFR-2を阻害し,腫瘍の血管新生を阻害する.
- ゼブラフィッシュの異種移植モデルにおいて,腫瘍の成長と転移を抑制する効果が確認されました.
結論:
- アジュフォレスティンAは,複数のメカニズムによって肺がんに対する強力な作用を示しています.
- 増殖,移動,血管新生を阻害する能力が 有望な候補となります
- Ajuforrestin Aは,非小細胞肺がん (NSCLC) の新しい治療薬としてさらなる開発を正当化しています.
関連する概念動画
PI3K/mTOR/AKT Signaling Pathway
3.9K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.9K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
TGF - β Signaling Pathway
7.6K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.6K
Tumor Progression
6.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K
MAPK Signaling Cascades
6.0K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.0K
Regulation of Angiogenesis and Blood Supply
2.7K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.7K


